Table 2.
Demographic and clinical characteristics of subjects included in the study at baseline
| Control | Alzheimer’s disease | Progressive MCI | Stable MCI | |
|---|---|---|---|---|
| Gender, n, female/male (% female) | 55/55 (50) | 42/53 (44) | 37/68 (35) | 22/46 (32) |
| Age at lumbar puncture, years | 76 (72–78) | 76 (70–80) | 75 (70–80) | 74 (70–80) |
| MMSE | 29 (29–30) | 24 (22–25)*** | 26 (25–28)*** | 28 (26–29)*** |
| ADAS-cog | 6.3 (4.0–8.0) | 17.7 (13.8–21.8)*** | 12.0 (9.67–15.3)*** | 9.67 (6.33–12.0)*** |
| Hippocampal volume | 3645 (3351–3854) | 2740 (2416–3208)*** | 2988 (2706–3271)*** | 3417 (3025–3764) |
| FDG-PET | 1.3 (1.2–1.4) | 1.1 (1.0–1.2)*** | 1.2 (1.1–1.3)*** | 1.2 (1.1–1.3) |
| CSF amyloid-β1–42, pg/ml | 220 (160–253) | 138 (122–159)*** | 139 (123–163)*** | 184 (133–245)*** |
| CSF total tau, pg/ml | 61 (50–86) | 111 (81–154)*** | 97 (75–129)*** | 69 (51–110)* |
| CSF phosphorylated tau, pg/ml | 20 (16–28) | 36 (29–49)*** | 38 (26–48)*** | 24 (18–39)* |
| CSF neurogranin, pg/ml | 304 (161–453) | 485 (349–744)*** | 492 (330–672)*** | 386 (190–582) |
The values presented are median (IQR).
*P < 0.05 versus controls; **P < 0.01 versus controls; ***P < 0.001 versus controls.